28 Plays on Bird Flu 
 
Company Mkt Cap YTD % Chg 2/19/06 Price Key Product 
Chiron (CHIR) $8.5 B 2.1 $45.37  Fluvirin, FDA-approved vs. influenza A *** 
Gilead Sciences (GILD) 28.1 B 16.9 $61.46  Invented Tamiflu, leading drug to lessen H5N1 symptoms 
Forest Labs (FRX) 15.2 B 15.3 $46.89  Flumadine, FDA-approved to treat influenza A  
Endo Pharma (ENDP) 3.9 B -1.5 $29.80  Symmetrel, FDA-approved to treat influenza A * 
Sanofi-Aventis (SNY) 123 B 0.7 $44.20  Rec'd $100M grant from U.S. to develop H5N1 vaccine 
MedImmune (MEDI) 8.7 B 2.8 $36.01  Flumist, FDA-approved to treat influenza A *** 
Roche Holding (RHHBY) 103 B -4 $72.95  Tamiflu, leading H5N1, licensed from Gilead **** 
Carrington Labs (CARN) 53.5 M 4.9 $4.96  Rec'd $6M grant from U.S. to develop H5N1 vaccine 
Novartis (NVS) 127 B 4.2 $54.68  Announced plan to develop RNAi therapeutic for H5N1 
GlaxoSmithKline (GSK) 144 B 1.5 $51.23  Relenza and Flurarix, FDA-approved to treat influenza A *** 
Quest Diagnostics (DGX) 10 B 2.6 $52.80  DNA test for flu viruses 
Acambis (ACAM) 419 M 8.3 $7.83  Ampligen, said to amplify effectiveness of Tamiflu 
Dynavax Technologies (DVAX) 181 M 44.9 $6.10  Imunostimulatory sequence technology to target virus 
Vical (VICL) 118 M 0 $4.20  Developing DNA-based vaccine vs. H5N1 
AVANT Immuno (AVAN) 136 M -2.1 $1.84  Announced plans to research H5N1 vaccine 
AVI BioPharma (AVII) 333 M 118.8 $7.55  Antisense-based therapeutic 
Crucell (CRXL) 1.0 B -2.5 $24.96  PER.C6 tech used by Sanofi in H5N1 vaccine development 
Hemispherx BioPharm (HEB) 169 M 44.7 $3.14  Alferon, stimulates Interferon to defend vs. H5N1 
Novavax (NVAX) 225 M 19.5 $4.60  Technology may help speed H5N1 vaccine development 
Quidel (QDEL) 307 M -13.2 $9.34  FDA-approved test for influenza A & B 
BioCryst Pharm (BCRX) 504 M 13.9 $19.07  Peramivir, which may inhibit H5N1 virus 
Alnylam Pharm (ALNY) 373 M 5.1 $14.04  Announced plan to develop RNAi therapeutic for H5N1 
Generex Biotechnology (GNBT) 102 M 95.2 $1.62  Developing anti-H5N1 vaccine w/ Antigen Express tech 
CombiMatrix Group (CBMX) 62 M 17.5 $1.61  Microarray for typing flu viruses 
Qiagen (QGEN) 2.0 B 15 $13.51  DNA test for flu viruses 
Sinovac Biotech (SVA) 156 M 3.5 $4.15  Anflu, licensed in China as antiflu vaccine 
Peregrine Pharma (PPHM) 254 M 57 $1.46  Tarcivin, chimeric antibody in preclinical trials  
NanoViricides (NNVC)  137 $1.92  FluCide I, antiviral targeting H5N1 ** 
Source: PharmaWeek; MSN Money; company reports
* Proven ineffective against H5N1 in current formulation
** Trades on Pink Sheets, an unregulated over-the-counter stock exchange
*** Has several additional potential therapies in development
**** Swiss company that trades on OTC in U.S. in form of ADRs